KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Intangibles (2016 - 2025)

Pfizer (PFE) has disclosed Intangibles for 17 consecutive years, with $53.7 billion as the latest value for Q4 2025.

  • Quarterly Intangibles fell 3.03% to $53.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $53.7 billion through Dec 2025, down 3.03% year-over-year, with the annual reading at $53.7 billion for FY2025, 3.03% down from the prior year.
  • Intangibles for Q4 2025 was $53.7 billion at Pfizer, up from $51.3 billion in the prior quarter.
  • The five-year high for Intangibles was $64.9 billion in Q4 2023, with the low at $25.1 billion in Q4 2021.
  • Average Intangibles over 5 years is $43.8 billion, with a median of $42.7 billion recorded in 2022.
  • The sharpest move saw Intangibles decreased 18.83% in 2021, then surged 72.47% in 2022.
  • Over 5 years, Intangibles stood at $25.1 billion in 2021, then soared by 72.47% to $43.4 billion in 2022, then soared by 49.64% to $64.9 billion in 2023, then decreased by 14.62% to $55.4 billion in 2024, then fell by 3.03% to $53.7 billion in 2025.
  • According to Business Quant data, Intangibles over the past three periods came in at $53.7 billion, $51.3 billion, and $52.7 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.